Table 1 Demographic and clinicopathological characteristics and the associations with DNA methylation age for 1076 female breast cancer patients (N, %)
From: Decelerated DNA methylation age predicts poor prognosis of breast cancer
Characteristics | Total | DNAm age (quartile)b | P value a | |||
|---|---|---|---|---|---|---|
First | Second | Third | Fourth | |||
Age (years) | ||||||
< 40 | 96 (8.9) | 52 (19.3) | 20 (7.4) | 13 (4.8) | 11 (4.1) | < 0.01 |
40–60 | 496 (46.1) | 145 (53.9) | 148 (55.0) | 115 (42.8) | 88 (32.7) | |
> 60 | 484 (45.0) | 72 (26.8) | 101 (37.5) | 141 (52.4) | 170 (63.2) | |
Race | ||||||
African American | 178 (16.5) | 72 (26.8) | 40 (14.9) | 35 (13.0) | 31 (11.5) | < 0.01 |
White or other | 898 (83.5) | 197 (73.2) | 229 (85.1) | 234 (87.0) | 238 (88.5) | |
Menopausal status | ||||||
Premenopausal | 229 (21.3) | 80 (29.7) | 57 (21.2) | 54 (20.1) | 38 (14.1) | < 0.01 |
Post-menopausal | 736 (68.4) | 153 (56.9) | 185 (68.8) | 187 (69.5) | 211 (78.4) | |
Unknown | 111 (10.3) | 36 (13.4) | 27 (10.0) | 28 (10.4) | 20 (7.4) | |
ER | ||||||
Negative | 178 (16.6) | 99 (36.8) | 53 (19.7) | 20 (7.4) | 6 (2.2) | < 0.01 |
Positive | 588 (54.6) | 95 (35.3) | 140 (52.0) | 161 (59.9) | 192 (71.4) | |
Unknown | 310 (28.8) | 75 (27.9) | 76 (28.3) | 88 (32.7) | 71 (26.4) | |
PR | ||||||
Negative | 251 (23.3) | 122 (45.4) | 67 (24.9) | 36 (13.4) | 26 (9.7) | < 0.01 |
Positive | 512 (47.6) | 70 (26.0) | 126 (46.8) | 145 (53.9) | 171 (63.6) | |
Unknown | 313 (29.1) | 77 (28.6) | 76 (28.3) | 88 (32.7) | 72 (26.7) | |
HER2 | ||||||
Negative | 644 (59.9) | 156 (58.0) | 162 (60.2) | 155 (57.6) | 171 (63.5) | 0.33 |
Equivocal/positive | 118 (11.0) | 37 (13.7) | 31 (11.5) | 24 (9.0) | 26 (9.7) | |
Unknown | 314 (29.1) | 76 (28.3) | 76 (28.3) | 90 (33.4) | 72 (26.8) | |
PAM50 | ||||||
Luminal A | 229 (21.3) | 25 (9.3) | 51 (19.0) | 71 (26.4) | 82 (30.5) | < 0.01 |
Luminal B | 122 (11.3) | 22 (8.2) | 25 (9.3) | 28 (10.4) | 47 (17.5) | |
HER2-enriched & Basal-like | 155 (14.4) | 84 (31.2) | 41 (15.2) | 22 (8.2) | 8 (3.0) | |
Unknown | 570 (53.0) | 138 (51.3) | 152 (56.5) | 148 (55.0) | 132 (49.0) | |
Clinical stage | ||||||
I/II | 568 (52.8) | 136 (50.6) | 149 (55.4) | 136 (50.6) | 147 (54.6) | 0.26 |
III/IV | 187 (17.4) | 56 (20.8) | 38 (14.1) | 44 (16.3) | 49 (18.2) | |
Unknown | 321 (29.8) | 77 (28.6) | 82 (30.5) | 89 (33.1) | 73 (27.1) | |